# A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin 0.4 mg Tablets, in Healthy Adult Male Subjects, Under Fed Conditions

> **NCT07091669** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Berlin-Chemie AG Menarini Group** · enrollment: 46 (estimated)

## Conditions studied

- Healthy Volunteers
- Male

## Interventions

- **DRUG:** Tamsulosin (0.4 mg/j)
- **DRUG:** Tamsulosin (0.4 mg/j)

## Key facts

- **NCT ID:** NCT07091669
- **Lead sponsor:** Berlin-Chemie AG Menarini Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-16
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-11-22
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07091669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07091669, "A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin 0.4 mg Tablets, in Healthy Adult Male Subjects, Under Fed Conditions". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07091669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*